DAVY VIEW

Amryt has today announced a distribution agreement with Swixx BioPharma (Swixx), which will distribute Myalepta across 17 jurisdictions in Central and Eastern Europe (CEE). Myalepta is currently Amryt’s bestselling product, accounting for c.60% of revenues. Today’s announcement underpins our growth forecasts, which we leave unchanged. As a reminder, the next major catalyst for the stock will be in late Q3, when we expect AP101 phase III trial results.